Detail akcie SIGA TECH online

Business Summary: SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks, vaccines and therapies for emerging infectious diseases, and health preparedness. The Company's lead product is TPOXX, also known as tecovirimat and ST-246, an orally administered and intravenous (IV) formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. TPOXX is a novel small-molecule drug and the United States maintains a supply of TPOXX under Project BioShield. The European Medicines Agency and United Kingdom approvals include labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox. It uses third parties known as contract manufacturing organizations to procure commercial raw materials and supplies, and to manufacture TPOXX.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, SIGA Technologies Inc revenues increased 26% to $139.9M. Net income increased from $33.9M to $68.1M. Revenues reflect Product sales and supportive services increase of 51% to $130.7M. Net income benefited from Pharmaceutical segment income increase of 96% to $83.6M. Basic Earnings per Share excluding Extraordinary Items increased from $0.46 to $0.95.